Patents by Inventor Atsushi Kuwahara
Atsushi Kuwahara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117304Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergie neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.Type: ApplicationFiled: December 14, 2023Publication date: April 11, 2024Applicants: KYOTO UNIVERSITY, SUMITOMO PHARMA CO., LTD.Inventors: Jun TAKAHASHI, Daisuke DOI, Kenji YOSHIDA, Atsushi KUWAHARA, Masayo TAKAHASHI
-
Patent number: 11898163Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.Type: GrantFiled: April 24, 2017Date of Patent: February 13, 2024Assignees: KYOTO UNIVERSITY, SUMITOMO PHARMA CO., LTD.Inventors: Jun Takahashi, Daisuke Doi, Kenji Yoshida, Atsushi Kuwahara, Masayo Takahashi
-
Publication number: 20240026123Abstract: The present invention provides a resin additive capable of imparting low temperature impact properties to a resin material, a resin composition comprising the resin additive, and a molded article formed from the resin composition. The resin additive of the present invention is a polymer having a structural unit (a1) derived from the following monomer (1); the resin composition of the present invention comprises the resin additive and a resin material; and the molded article of the present invention is formed from the resin composition.Type: ApplicationFiled: August 8, 2023Publication date: January 25, 2024Applicant: Mitsubishi Chemical CorporationInventors: Yutaka AOKI, Hiroshi NIINO, Eiko OKAMOTO, Hiroyuki NISHII, Masahiro UEDA, Masashi IIMORI, Atsushi KUWAHARA
-
Publication number: 20240024230Abstract: The present invention addresses the problem of providing an oral pouch product containing a novel oral composition to which a cool feeling (also referred to as sense of coolness, fresh taste, or the like) is imparted. The problem is solved by an oral pouch product formed from an oral composition containing nicotine, a sugar alcohol, and a cool feeling fragrance and a packaging material for packaging the oral composition. The weight ratio of the sugar alcohol to the cool fragrance is 10-1000.Type: ApplicationFiled: September 29, 2023Publication date: January 25, 2024Applicant: JAPAN TOBACCO INC.Inventors: Masashi FURUKOSHI, Atsushi KUWAHARA, Sosuke WATASE
-
Publication number: 20230310614Abstract: An object of the present invention is to provide a vehicle and a composition for transplantation comprising retinal tissue and the vehicle, which are for the treatment of retinal degenerative diseases such as retinitis pigmentosa (RP) and are suitable for the subretinal transplantation of retinal tissue. The vehicle for transplantation of the present invention is a vehicle for transplantation for subretinally transplanting retinal tissue, the vehicle having a viscosity of 5 to 500 mPa·s at a shear rate of 2 (1/s) at 25° C., and comprising hyaluronic acid and a pharmaceutically acceptable aqueous liquid. The composition for transplantation of the present invention comprises transplant retinal tissue and the vehicle for transplantation of the present invention.Type: ApplicationFiled: September 10, 2021Publication date: October 5, 2023Applicants: Sumitomo Pharma Co., Ltd., RikenInventors: Michiko Mandai, Masayo Takahashi, Tatsuya Kamei, Keiichi Ono, Kenji Watari, Atsushi Kuwahara
-
Patent number: 11724005Abstract: The invention provides a method for producing a ciliary marginal zone stem cell induced to differentiate from a pluripotent stem cell, including either the following step (1) or step (2), or both of these steps: (1) a step of floating culturing cells obtained from a cell aggregate containing a ciliary marginal zone-like structure induced to differentiate from pluripotent stem cells, thereby obtaining a retinosphere; and (2) a step of collecting stage specific embryonic antigen-1 positive cells from cells obtained from a cell aggregate containing a ciliary marginal zone-like structure induced to differentiate from pluripotent stem cells.Type: GrantFiled: October 16, 2014Date of Patent: August 15, 2023Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Atsushi Kuwahara, Yoshiki Sasai
-
Publication number: 20230118524Abstract: Polyorganosiloxane-containing polymer particles comprising: a polymer (A) comprising a polyorganosiloxane (A1) and a first vinyl polymer (A2); and a second vinyl polymer (B), wherein a proportion of particles satisfying formula (1) is less than 60%: M/L>0.1??(1), wherein L is a diameter of each particle of the polyorganosiloxane-containing polymer particles, as determined in an observation using a transmission electron microscope with respect to a cross section of a resin piece obtained by dispersing the polyorganosiloxane-containing polymer particles in a resin, and M is a maximum domain length of the polyorganosiloxane (A1) in the observation.Type: ApplicationFiled: December 9, 2022Publication date: April 20, 2023Applicant: Mitsubishi Chemical CorporationInventors: Atsushi KUWAHARA, Hiroya ARAI, Ai KIWA, Shinji MATSUOKA
-
Patent number: 11371016Abstract: The present invention provides a method for producing a retinal cell or a retinal tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension in a medium containing a Wnt signal transduction pathway inhibiting substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a Wnt signal transduction pathway inhibiting substance in a medium containing a BMP signal transduction pathway activating substance to obtain an aggregate containing a retinal cell or a retinal tissue.Type: GrantFiled: April 21, 2017Date of Patent: June 28, 2022Assignees: SUMITOMO PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi Kuwahara, Suguru Yamasaki, Yoshiki Sasai, Masayo Takahashi
-
Publication number: 20220170098Abstract: The method disclosed herein is for evaluating the quality of a transplant neural retina by sampling a part or the whole of a cell aggregate containing a neural retina having an epithelial structure derived from a pluripotent stem cell as a sample for quality evaluation.Type: ApplicationFiled: March 13, 2020Publication date: June 2, 2022Applicants: Sumitomo Dainippon Pharma Co., Ltd., Riken, Sumitomo Chemical Company, LimitedInventors: Atsushi Kuwahara, Kenji Watari, Keizo Matsushita, Suguru Yamasaki, Michiko Mandai, Masayo Takahashi
-
Publication number: 20220119764Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.Type: ApplicationFiled: January 3, 2022Publication date: April 21, 2022Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI (deceased), Masayo TAKAHASHI
-
Publication number: 20220112457Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.Type: ApplicationFiled: December 22, 2021Publication date: April 14, 2022Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI (deceased), Masayo TAKAHASHI
-
Patent number: 11214772Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.Type: GrantFiled: October 23, 2015Date of Patent: January 4, 2022Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi Kuwahara, Suguru Yamasaki, Yasushi Hiramine, Yoshiki Sasai, Masayo Takahashi
-
Patent number: 11214771Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.Type: GrantFiled: October 23, 2015Date of Patent: January 4, 2022Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Atsushi Kuwahara, Suguru Yamasaki, Yasushi Hiramine, Yoshiki Sasai, Masayo Takahashi
-
Patent number: 11111476Abstract: The present invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure, including a step of culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more and 100% or less of the tissue in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway and a substance inhibiting the FGF signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the “cell aggregate in which a RPE65 gene-expressing cell does not appear” thus obtained in a serum-free medium or serum-containing medium each free of a substance acting on the Wnt signal pathway and so on. According to the production method of the present invention, a ciliary marginal zone-like structure can be produced with high efficiency.Type: GrantFiled: February 5, 2019Date of Patent: September 7, 2021Assignees: Sumitomo Chemical Company, Limited, RIKENInventors: Atsushi Kuwahara, Yoshiki Sasai
-
Publication number: 20210230558Abstract: An object of the present invention is to provide a dispersion of pluripotent stem cells and a pluripotent stem cell product having a suitable quality as a pharmaceutical or a raw material for producing a pharmaceutical which can be stored and distributed, and a method for producing the same. The method for producing a pluripotent stem cell product of the present invention comprises (1) culturing pluripotent stem cells in an undifferentiation maintenance medium; (2) suspending the pluripotent stem cells cultured in step (1) in a first medium for suspending cells containing a ROCK inhibitor; (3) replacing the medium for suspending cells of a suspension obtained in step (2) with a medium for cryopreservation to obtain a cell dispersion solution consisting of the medium for cryopreservation and the pluripotent stem cells dispersed in the medium for cryopreservation; and (4) filling the cell dispersion solution obtained in step (3) into an airtight container so as to be in an airtight state.Type: ApplicationFiled: July 10, 2019Publication date: July 29, 2021Applicants: Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Chemical Company, LimitedInventors: Atsushi Kuwahara, Naoki Takamura, Ayaka Fujiki, Tetsuya Hayama, Hidetaka Ohara
-
Patent number: 10982092Abstract: To enhance adhesion between a resin and a glass filler and at the same time to disperse a rubber in the resin to thereby improve mechanical properties of a molded body. Provided is a resin composition containing an engineering plastic (A), a glass filler (B) and a rubber-containing graft polymer (C), wherein a ratio of an acrylonitrile-derived component in a chloroform-soluble component of the resin composition is not more than 2.0 mass %, a content of a fatty acid in 100 parts by mass of the resin composition is not more than 0.03 parts by mass, a total content of calcium and magnesium in 100 parts by mass of a dry sample of the resin composition extracted with chloroform is not more than 0.0008 parts by mass, and a content of aluminum is not more than 0.0008 parts by mass. Also provided is a resin composition further containing a salt (D) of an alkali metal and a strong acid. The engineering plastic (A) is preferably an aromatic polycarbonate resin.Type: GrantFiled: November 26, 2018Date of Patent: April 20, 2021Assignee: Mitsubishi Chemical CorporationInventors: Shinji Matsuoka, Atsushi Kuwahara, Masahiro Ueda
-
Patent number: 10810407Abstract: A specific region such as a continuous epithelial structure is automatically detected in a cell aggregate. A region detecting method includes an input step (S01) of inputting an image obtained by imaging a cell aggregate, an outline detecting step (S02) of detecting an outline of the cell aggregate together with an order along the outline from the input image, a region detecting step (S03) of detecting a specific region included in the cell aggregate based on the detected outline and order, and an output step (S04) of outputting information indicating the detected region.Type: GrantFiled: November 25, 2016Date of Patent: October 20, 2020Assignees: RIKEN, Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Chemical Company, LimitedInventors: Satoru Okuda, Mototsugu Eiraku, Atsushi Kuwahara
-
Publication number: 20200216796Abstract: An object of the present invention is to provide a method for preserving neural tissue for several hours to several weeks without freezing, a preservation solution therefor, a transport method for neural tissue in accordance with the method and using the preservation solution, and a composition for transplantation. The preservation method for neural tissue, comprising preserving neural tissue in a preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM at a preservation temperature of 8° C. to 30° C. The preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM, for preserving neural tissue derived from pluripotent stem cells at a preservation temperature of 8° C. to 30° C.Type: ApplicationFiled: July 20, 2018Publication date: July 9, 2020Applicants: Riken, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Michiko Mandai, Masayo Takahashi, Atsushi Kuwahara, Kenji Watari, Keizo Matsushita
-
Publication number: 20200208103Abstract: The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.Type: ApplicationFiled: July 20, 2018Publication date: July 2, 2020Applicants: RIKEN, SUMITOMO DAINIPPON PHARMA CO., LTD., SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Hideya SAKAGUCHI, Yoshiki SASAI (deceased), Mototsugu EIRAKU, Daiki NUKAYA, Atsushi KUWAHARA
-
Publication number: 20190169570Abstract: The present invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure, including a step of culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more and 100% or less of the tissue in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway and a substance inhibiting the FGF signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the “cell aggregate in which a RPE65 gene-expressing cell does not appear” thus obtained in a serum-free medium or serum-containing medium each free of a substance acting on the Wnt signal pathway and so on. According to the production method of the present invention, a ciliary marginal zone-like structure can be produced with high efficiency.Type: ApplicationFiled: February 5, 2019Publication date: June 6, 2019Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Atsushi KUWAHARA, Yoshiki SASAI